Vertex Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: VRTX · Form: 8-K · Filed: May 15, 2024 · CIK: 875320
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: VRTX
TL;DR
VRTX filed an 8-K for a shareholder vote - details to follow.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on May 15, 2024, to report on the submission of matters to a vote of security holders. The filing indicates that the company is seeking approval or has held a vote on certain corporate matters, though specific details of the vote are not provided in this excerpt. The company is incorporated in Massachusetts and headquartered in Boston.
Why It Matters
This filing signals that Vertex Pharmaceuticals is engaging in corporate governance processes requiring shareholder input, which can impact company direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial or operational risks.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- May 15, 2024 (date) — Date of Report
- Massachusetts (location) — State of Incorporation
- Boston (location) — Principal Executive Offices City
- 50 Northern Avenue (address) — Principal Executive Offices Street
FAQ
What specific matters were submitted for a vote of security holders?
The provided excerpt of the 8-K filing does not specify the exact matters submitted for a vote of security holders; it only indicates that such a submission occurred.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 15, 2024, which is also the date of the report.
What is Vertex Pharmaceuticals' state of incorporation?
Vertex Pharmaceuticals Incorporated is incorporated in Massachusetts.
Where are Vertex Pharmaceuticals' principal executive offices located?
Vertex Pharmaceuticals' principal executive offices are located at 50 Northern Avenue, Boston, Massachusetts, 02210.
What is the purpose of this Form 8-K filing?
This Form 8-K filing is to report the submission of matters to a vote of security holders.
Filing Stats: 661 words · 3 min read · ~2 pages · Grade level 14.8 · Accepted 2024-05-15 16:12:18
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
Filing Documents
- vrtx-20240515.htm (8-K) — 46KB
- 0000875320-24-000142.txt ( ) — 168KB
- vrtx-20240515.xsd (EX-101.SCH) — 2KB
- vrtx-20240515_lab.xml (EX-101.LAB) — 21KB
- vrtx-20240515_pre.xml (EX-101.PRE) — 12KB
- vrtx-20240515_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May 15, 2024 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting: Proposal No. 1 : Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025: For Against Abstain Non-Votes Sangeeta Bhatia 221,206,626 808,512 182,981 11,540,149 Lloyd Carney 213,533,037 8,478,558 186,524 11,540,149 Alan Garber 220,695,587 1,315,689 186,843 11,540,149 Reshma Kewalramani 221,328,875 695,546 173,698 11,540,149 Michel Lagarde 221,776,280 234,937 186,902 11,540,149 Jeffrey Leiden 217,823,643 4,195,522 178,954 11,540,149 Diana McKenzie 218,220,365 3,797,695 180,059 11,540,149 Bruce Sachs 207,616,033 14,397,759 184,327 11,540,149 Jennifer Schneider 221,774,054 240,910 183,155 11,540,149 Nancy Thornberry 221,772,658 241,378 184,083 11,540,149 Suketu Upadhyay 221,237,300 770,815 190,004 11,540,149 Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: For Against Abstain Non-Votes 229,460,523 3,987,619 290,126 0 Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2023 compensation program for the Company's named executive officers: For Against Abstain Non-Votes 202,098,575 19,223,784 875,760 11,540,149 Proposal No. 4: Based upon the following votes, the shareholders approved a shareholder proposal regar
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: May 15, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer